These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21735114)

  • 1. Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment.
    Le Scodan R; Massard C; Jouanneau L; Coussy F; Gutierrez M; Kirova Y; Lerebours F; Labib A; Mouret-Fourme E
    J Neurooncol; 2012 Jan; 106(1):169-76. PubMed ID: 21735114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score.
    Le Scodan R; Massard C; Mouret-Fourme E; Guinebretierre JM; Cohen-Solal C; De Lalande B; Moisson P; Breton-Callu C; Gardner M; Goupil A; Renody N; Floiras JL; Labib A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):839-45. PubMed ID: 17544592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.
    Le Scodan R; Jouanneau L; Massard C; Gutierrez M; Kirova Y; Cherel P; Gachet J; Labib A; Mouret-Fourme E
    BMC Cancer; 2011 Sep; 11():395. PubMed ID: 21929800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review.
    Dawood S; Gonzalez-Angulo AM; Albarracin C; Yu TK; Hortobagyi GN; Buchholz TA; Woodward WA
    Cancer; 2010 Jul; 116(13):3084-92. PubMed ID: 20564633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.
    Bartsch R; Berghoff A; Pluschnig U; Bago-Horvath Z; Dubsky P; Rottenfusser A; DeVries C; Rudas M; Fitzal F; Dieckmann K; Mader RM; Gnant M; Zielinski CC; Steger GG
    Br J Cancer; 2012 Jan; 106(1):25-31. PubMed ID: 22127284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment after whole-brain radiotherapy may improve survival in RPA class II/III breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Ma J; Cai G; Yang Z; Cao L; Chen X; Guo X; Chen J
    J Neurooncol; 2013 Sep; 114(2):181-9. PubMed ID: 23743596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients.
    Fokas E; Henzel M; Hamm K; Grund S; Engenhart-Cabillic R
    Tumori; 2012 Nov; 98(6):768-74. PubMed ID: 23389365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era.
    Karam I; Nichol A; Woods R; Tyldesley S
    Radiat Oncol; 2011 Dec; 6():181. PubMed ID: 22204610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
    Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
    Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer.
    Ono M; Ando M; Yunokawa M; Nakano E; Yonemori K; Matsumoto K; Kouno T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
    Int J Clin Oncol; 2009 Feb; 14(1):48-52. PubMed ID: 19225924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
    Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2111-7. PubMed ID: 21497451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems.
    Viani GA; Castilho MS; Salvajoli JV; Pellizzon AC; Novaes PE; Guimarães FS; Conte MA; Fogaroli RC
    BMC Cancer; 2007 Mar; 7():53. PubMed ID: 17386108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?
    Nieder C; Nestle U; Motaref B; Walter K; Niewald M; Schnabel K
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):297-302. PubMed ID: 10661335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors.
    Antoni D; Clavier JB; Pop M; Schumacher C; Lefebvre F; Noël G
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):630-7. PubMed ID: 23582409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.
    Park IH; Ro J; Lee KS; Nam BH; Kwon Y; Shin KH
    Ann Oncol; 2009 Jan; 20(1):56-62. PubMed ID: 18664558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.